Co-Diagnostics Expands CoSara's South Asia Market to $13 Billion
Co-Diagnostics has signed an agreement for CoSara Diagnostics, the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises, to significantly expand its commercial and distribution territory across South Asia to now include Bangladesh, Pakistan, Nepal, and Sri Lanka. The expansion significantly increases CoSara's addressable market across South Asia, bringing the total regional opportunity to an estimated $13B based on internal analyses and third-party market data. It also supports CoSara's plans to commercialize the CoSara PCR Pro point-of-care instrument and tests as well as the SARAGENE product line across the region, subject to applicable regulatory approvals in each jurisdiction. As part of this expansion, CoSara is working to establish distribution channels in these newly added markets, including evaluating regulatory pathways, identifying priority customer segments, and engaging regional distribution partners.
